Kowa Company, Ltd. grants Abbott exclusive rights to market pitavastatin calcium, in Australia and New Zealand

Kowa Company, Ltd. grants Abbott exclusive rights

28.06.2011

Kowa Company, Ltd. grants Abbott exclusive rights to market pitavastatin calcium, a lipid-lowering drug, in Australia and New Zealand

Wokingham, UK, 28th June 2010, following an enthusiastic expansion programme into new markets, Kowa Company, Ltd. President: Yoshihiro Miwa, headquartered in Nagoya, Japan, has granted Abbott, headquartered in Illinois, USA the exclusive license to distribute and market pitavastatin calcium (brand name Livalo), a lipid-lowering drug, in Australia and New Zealand. This agreement means that pitavastatin will now be marketed in five continents.

Download Material

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more.

X